Squarepoint Ops LLC lifted its stake in Zoetis Inc (NYSE:ZTS) by 38.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 54,471 shares of the company’s stock after purchasing an additional 14,998 shares during the quarter. Squarepoint Ops LLC’s holdings in Zoetis were worth $6,787,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. Tarbox Family Office Inc. lifted its holdings in shares of Zoetis by 74.4% in the 3rd quarter. Tarbox Family Office Inc. now owns 218 shares of the company’s stock worth $27,000 after acquiring an additional 93 shares during the last quarter. Prestige Wealth Management Group LLC purchased a new stake in Zoetis in the 2nd quarter worth about $27,000. Tradewinds Capital Management LLC bought a new stake in Zoetis in the third quarter worth about $31,000. Altshuler Shaham Ltd lifted its stake in Zoetis by 198.8% in the second quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock worth $29,000 after purchasing an additional 169 shares during the last quarter. Finally, Atlas Capital Advisors LLC purchased a new position in shares of Zoetis during the third quarter valued at approximately $33,000. Hedge funds and other institutional investors own 90.17% of the company’s stock.
In other Zoetis news, EVP Kristin C. Peck sold 11,500 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $117.16, for a total transaction of $1,347,340.00. Following the transaction, the executive vice president now owns 44,877 shares of the company’s stock, valued at approximately $5,257,789.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $120.05, for a total transaction of $735,066.15. Following the transaction, the executive vice president now directly owns 41,698 shares in the company, valued at approximately $5,005,844.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 125,600 shares of company stock valued at $15,021,964. 0.29% of the stock is currently owned by corporate insiders.
A number of research analysts have recently commented on ZTS shares. SunTrust Banks upped their target price on Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a research note on Tuesday, August 13th. Craig Hallum increased their price target on Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Morgan Stanley raised their price target on Zoetis from $100.00 to $136.00 and gave the stock an “equal weight” rating in a research note on Monday, September 30th. Argus set a $140.00 price objective on Zoetis and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, Goldman Sachs Group started coverage on Zoetis in a research report on Monday, September 9th. They issued a “conviction-buy” rating and a $145.00 price objective on the stock. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $125.20.
Shares of NYSE:ZTS opened at $119.91 on Tuesday. The firm has a market cap of $57.40 billion, a PE ratio of 38.31, a price-to-earnings-growth ratio of 2.76 and a beta of 0.80. The firm’s 50 day simple moving average is $122.50 and its 200-day simple moving average is $118.46. Zoetis Inc has a one year low of $78.90 and a one year high of $130.20. The company has a debt-to-equity ratio of 2.47, a quick ratio of 3.02 and a current ratio of 4.39.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. Zoetis had a return on equity of 70.78% and a net margin of 23.76%. The firm had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.58 billion. During the same quarter in the previous year, the business earned $0.83 earnings per share. Zoetis’s quarterly revenue was up 7.0% on a year-over-year basis. Equities research analysts predict that Zoetis Inc will post 3.6 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Tuesday, October 22nd were issued a dividend of $0.164 per share. The ex-dividend date was Monday, October 21st. This represents a $0.66 annualized dividend and a yield of 0.55%. Zoetis’s payout ratio is currently 21.09%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: Nikkei 225 Index
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.